Targets › DDAH1
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Jan 2027.
Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation. (UniProt, O94760)
Open in Phaseline: the race on DDAH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | Meropenem-Vaborbactam Beta-lactam antibiotic combined with a beta-lactamase inhibitor; meropenem is a carbapenem | DDAH1 | Phase 2 | Acute Pyelonephritis | Jan 2027 |
Acute Pyelonephritis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.